Answers are grounded in this paper and cite their sources.
In this large national dataset, use of diabetes technologies was found to differ across socioeconomic groups. For nationally subsidised CGM, use was similar across socioeconomic groups with the exception of the most disadvantaged quintile, an important finding requiring further investigation into barriers to CGM use within a nationally subsidised model. User pays funding models for pump therapy result in lower use with socioeconomic disadvantage, highlighting inequities in this funding approach. For the full benefits of diabetes technology to be realised, equitable access to pump therapy needs to be a health policy priority.
No takes yet. Share an insight, caveat, or question.
Lomax et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: